Answers are grounded in this paper and cite their sources.
Mast cell activation mediated by immunoglobulin E (IgE) plays a crucial role in allergic diseases related to type I hypersensitivity including allergic rhinitis, asthma and atopic dermatitis (1, S1, S2). Binding of IgE to FcεRI receptors, followed by the cross-linkage of the IgE with the antigen, leads to the mast cell activation and secretion of preformed chemical mediators such as lipid mediators (leukotrienes and prostaglandins), granular contents (β-hexosaminidase and histamine), and inflammatory cytokines (interleukin [IL]-4, IL-6, IL-13, and tumor necrosis factor [TNF]-α), which initiates and exacerbates allergic inflammation (2, 3, S3-6). Thus, stabilization of mast cells or blocking the released mediators' action is a major strategy for the treatment of patients with type I hypersensitivity. While several agents such as non-steroidal anti-inflammatory drugs, steroids and immunosuppressants have been used, they more or less bring about adverse effects (4, S7). Therefore, safe candidates with both anti-allergic property and less toxicity have been expected. Recent studies have suggested that phlorotannins, which were extracted from the brown seaweed Ecklonia cava, have an inhibitory effect on FcεRI expression on basophils and IgE-mediated granule release (5, S8). Another experiment determined a dieckol, one of the active ingredients from the extract, exerted potent anti-inflammatory effects by abrogating cyclooxygenase-2 (COX2) and inducible nitric oxide synthase (iNOS) activation 6. Because there were no adverse effects when the dieckol was administered to mice (S9) and a chemical that possess a similar structure to dieckol suppressed basophil activation 5, we hypothesized that dieckol may also suppress mast cell activation in type I allergic responses. Therefore, we attempted to evaluate effects of dieckol on IgE-mediated activation of mast cells in vitro and experimental type I allergy in vivo. Detailed methods are described in Data S1–S4. In in vitro experiments, bone marrow-derived cultured mast cells (BMCMCs) from male WBB6F1-+/+ mice and LAD2, a human mast cell line, were used to determine the release of β-hexosaminidase and histamine, or cytokine expressions. Flow cytometry analysis was also conducted to detect the expression of FcεRI and IgE-binding to the surface of BMCMCs and LAD2 cells. The in vivo effects of dieckol were analysed using a passive cutaneous anaphylactic (PCA) reaction model of mice induced by both anti-2,4-dinitrophenol (DNP)-IgE and DNP-BSA. Because mast cells play a critical role in type I allergic responses (2,S2,S4), we examined the effect of dieckol on degranulation of mast cells by measuring β-hexosaminidase and histamine release. As shown in Fig. 1a and Fig. S1a, dieckol significantly and dose-dependently decreased the release of β-hexosaminidase and histamine in antigen-stimulated BMCMCs. Interestingly, chemical-induced degranulation of BMCMCs, which was triggered by an ionophore (A23187) or a histamine liberator (compound 48/80), was not suppressed by dieckol (Fig. S1c) . The inhibitory effects of dieckol on IgE-mediated degranulation were observed in LAD2 cells as well (Fig S1d,e). Moreover, dieckol did not affect the viability of both BMCMCs and LAD2 cells (Fig S1b,f). We also examined the inhibitory effects of dieckol on cytokine expressions of mast cells and found that dieckol suppressed the expression of various kinds of cytokines including IL-4, IL-6, IL-13 and TNF-α in not only activated BMCMCs but also LAD2 cells, respectively (Fig. 1b and Fig. S2). To determine these inhibitory mechanisms of dieckol, we next analysed the effects of dieckol on IgE-binding to FcεRI. Pretreatment of BMCMCs with dieckol before anti-DNP-IgE sensitization strongly reduced the binding of IgE to FcεRI compared to control cells (Fig. 1c). We attributed this to the downregulation of FcεRI; thus, flow cytometry analysis was carried out. As expected, dieckol treatment significantly reduced the expression of FcεRI (Fig. 1d). To examine the anti-allergic and mast cell-stabilizing effects of dieckol in vivo, we examined cutaneous extravasation of Evans blue dye in IgE-sensitized mice challenged with specific antigen with or without dieckol treatment. Compared to control mice, oral administration of dieckol 2 h prior to IgE sensitization markedly abrogated the PCA reaction in the mouse ear and reduced the leakage of Evans blue dye (Fig 2a,b). Abrogation of mast cell degranulation and oedematous changes was observed by histological analysis (Fig. 2c). Interestingly, suppression of PCA reaction was also observed when dieckol was administered 2 h before antigen stimulation (Fig S3a,b). We demonstrated the potency of dieckol to suppress mast cell activation and mast cell-mediated type I allergic responses caused by IgE-specific antigen, which was mainly due to the significant downregulation of FcεRI. Interestingly, dieckol treatment even after the IgE sensitization inhibited the PCA reaction, which may be explained by anti-inflammatory effects as reported previously 6. As far as we know, there has been no report that showed suppression of COX2 and iNOS resulted in the FcεRI downregulation. Therefore, another target molecule for dieckol may exist. Because relatively high dose was required to suppress the type I hypersensitivity reactions in our model, it will require some chemical structural modifications for using dieckol as a therapeutic agent. Identifying the precise mechanism and target molecules of dieckol will bring about a novel therapeutic approach for the prevention or treatment of mast cell-dependent allergic diseases. This work was supported by the grant from the Japan Society for the Promotion of Science and the Ministry of Education, Culture, Sports, Science, and Technology, Japan. Details are described in the Data S1–S3. All authors contributed this study. Details are described in the Data S1–S3. The authors have declared no conflicting interests. Data S1. Materials and methods. Data S2. Supplementary references. Data S3. Acknowledgements and authorship contribution in detail. Figure S1. (a) Histamine release of BMCMCs. Cells were incubated with dieckol, sensitized with IgE and stimulated with DNP-BSA. Three independent experiments were performed in triplicate and each data point represents the mean ± SE. *, ***; P < 0.05, 0.005 compared to control, respectively. (b) Dye exclusion test of BMCMCs. Cells were incubated with dieckol for 24 h and the viability was measured by a dye exclusion test. Three independent experiments were performed in triplicate and each data point represents the mean ± SE. (c) β-Hexosaminidase release of BMCMCs. BMCMCs were pretreated with dieckol and stimulated with 1 mm A23187 or 100 mg/ml compound 48/80. Three independent experiments were performed in triplicate and each data point represents the mean ± SE. (d) β-Hexosaminidase and (e) histamine release of LAD2 cells. Cells were incubated with dieckol, sensitized with IgE and stimulated with DNP-BSA. Three independent experiments were performed in triplicate and each data point represents the mean ± SE. ***, P < 0.005. (f) Dye exclusion test of LAD2 cells. Cells were incubated with dieckol for 24 h and the viability was measured by a dye exclusion test. Three independent experiments were performed in triplicate and each data point represents the mean ± SE. Figure S2. (a, c, e) Cytokine releases of BMCMCs. Cells were incubated with dieckol, sensitized with IgE and stimulated with DNP-BSA. Three independent experiments were performed in triplicate and each data point represents the mean ± SE. ***, P < 0.005. (b, d, f, g) Cytokine releases of LAD2 cells. Cells were incubated with dieckol, sensitized with IgE and stimulated with DNP-BSA. Three independent experiments were performed in triplicate and each data point represents the mean ± SE. *, ***; P < 0.05, 0.005 compared to control, respectively. Figure S3. Effect of dieckol on IgE-mediated PCA in vivo. (a) Representative photographs of each mice. Dieckol was administered 2 h before DNP-BSA stimulation. (b) Quantification of Evans blue leakage. Three independent experiments were performed in triplicate and each data point represents the mean ± SE. ***, P < 0.005. Figure S4. Structure of dieckol isolated from Ecklonia cava. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
No takes yet. Share an insight, caveat, or question.
Ahn et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: